The Management of Pulmonary Hypertension in Infants and Children
A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Pulmonary and Sleep Medicine".
Deadline for manuscript submissions: 20 December 2024 | Viewed by 2591
Special Issue Editors
Interests: pulmonary hypertension; cardiac dysfunction; echocardiographic assessment; biomarker; congenital diaphragmatic hernia; bronchopulmonary dysplasia
2. Center for Rare Diseases Bonn, Division of Congenital Malformations, University of Bonn, 53127 Bonn, Germany
Interests: pulmonary hypertension; cardiac dysfunction; echocardiographic assessment; biomarker; congenital diaphragmatic hernia; bronchopulmonary dysplasia
Special Issue Information
Dear Colleagues,
Pulmonary hypertension (PH) is one of the major contributors to short- and long-term morbidity and mortality in critically ill infants and children. In particular, infants and children with underlying congenital or acquired cardiovascular and pulmonary diseases are at risk when PH is diagnosed, with the need for long-term pharmaceutical treatment.
Therefore, the diagnosis and treatment of PH play an important role in its management in infants and children. Different diagnostic approaches, including biomarker profiles, echocardiographic assessments, and strategies such as multi-omic profiling, are becoming increasingly available and popular for the diagnosis of PH. Furthermore, multiple pharmaceutical treatment strategies have been evaluated in recent years in infants and children, offering insights into treatment effects and drug profiles.
This Special Issue will provide innovative and informative data on recent advantages in PH management, including new aspects of diagnosis and treatment of PH in pediatric populations. This Special Issue will focus on offering insights from retrospective and prospective clinical research of modern PH management to improve infant’s and children’s future medical care.
Dr. Lukas Schroeder
Dr. Florian Kipfmueller
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary hypertension
- biomarker profiles
- echocardiographic assessment
- multi-omic profiling
- pharmaceutical treatment
- infants
- children
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: The pulmonary artery pulsatility index provides no additional prognostic information in pediatric pulmonary arterial hypertension.
Authors: Faye E. Smits; Chantal Lokhorst; Marlies G. Haarman; Mark-Jan Ploegstra; Rolf M.F. Berger; Johannes Menno Douwes
Affiliation: University Medical Center Groningen
Abstract: Pulmonary artery pulsatility index (PAPi, calculated as (SPAP – DPAP) / mRAP) has been sug-gested a measure of right ventricular-vascular coupling (RVVC) and as a prognostic parameter in cardiovascular conditions, particularly right ventricular failure. This study investigated the re-lationship of PAPi and its components with disease severity RVVC, and outcomes in children with pulmonary arterial hypertension (PAH). We analyzed data from 111 children from the Dutch National Registry for PAH. PAPi was calculated from heart catheterization data and RVVC was determined as TAPSE/sPAP ratio via echocardiography. Disease severity was char-acterized by clinical, hemodynamic, and laboratory data. Cox proportional hazard modeling assessed PAPi's predictive value for transplant-free survival. There was no correlation between RVVC and PAPi (R=-0.208, P=0.111, n=60). PAPi correlated negatively with uric acid (R=-0.387, P